APA's Bill Echols, in his Fall, 1988 Newsletter column, discussed the strategy employed to address this issue. APA, in conjunction with the Center for Science in the Public Interest, filed a formal petition calling for the EPA to develop improved testing methods. This petition re- quired a formal response from EPA. In a remarkable turn of events, the internal EPA document drafted in the Office of Pesticides Programs in response to this petition essen- tially agreed with us about the need for more neurobehav- ioral evaluation of pesticides and on the essential frame- work for testing. After consultation with its Science Advi- sory Panel, EPA has agreed to adopt a number of new neurobehavioral testing guidelines. Wisely, they plan to use a common set of guidelines for use under both FIFRA and TSCA. The Division, through APA, has and will continue to comment on each stage of the development of these testing methods. In addition, we are working to insure their actual use in testimony before Congressional panels, meetings with EPA officials and the addition of report language in the FIFRA reauthorization bill. If we are ultimately successful in having EPA implement expanded testing of pesticides for neurobehavioral effects, and then in having the results of these tests applied appropriately to regulatory decisions, I believe that we will have accom- plished the important goal of advancing public health through the use of our scientific expertise. The crucial role of Bill Echols and other support from the APA Science Directorate cannot be overemphasized, illustrating the importance in forming a partnership between Divisional scientific expertise and APA Central Office expertise in governmental affairs. This model can usefully be applied to other regulatory areas where we have an interest. I have been very impressed with how the well-targeted efforts of a relatively few individuals, when supported by the member- ship of a scientific society, can have a major impact on public policy.

I would conclude this two-part series on Division in- volvement in public affairs by acknowledging the flowering of activities by many Division members in these and other areas. Other public policy activities in which Division members have played an important role include ethical guidelines for animal and human experimentation, the regulation of animal and human experimentation, the research budgets of a number of Federal agencies, drug abuse control policy, problems of tobacco consumption, science training, research administration, and more. Divi- sion members hold a number of important posts in the Federal government and serve on many advisory boards and grant review panels. I believe these "service" endeavors to be not only an important obligation to the public that supports our research, but an intellectually stimulating and professionally satisfying activity for scientists and practi- tioners. I applaud the membership's continued involve-

ment in this area. I also believe that the success of our partnership with the APA Central Office in the public affairs area is one of the major benefits of continued membership in the Association, despite the problems which the Science Divisions have experienced in recent years.

Pharmacotherapy for Drug Abuse

The Senate Judiciary Committee, under the leadership of Senator Joseph R. Biden, Jr. (D-Delaware), issued a report on Dec. 13, 1989 entitled "Pharmacotherapy: A Strategy for the 1990's," calling for a major expansion of the federal government's role in developing new drug treat- ments for drug abuse. The report recommends an expendi- ture of $1 billion over the next decade for research and development in this area, as well as changes in FDA proce- dures for approving drug abuse medications. Legislation to implement these recommendations is being prepared for early introduction in Congress. The report acknowledges the critical interrelationship of pharmaco-logical and behavioral treatments and provides a compelling rationale for a national strategy to expand our efforts in drug devel- opment. This initiative could have a major impact on drug abuse research and treatment. Interested Division mem- bers should follow the progress of this significant legislative development and provide their expertise and opinions to help ensure that Congress acts wisely on this matter.

American Psychological Society

Included in this issue of the Newsletter is a membership application form that the American Psychological Society requested that we distribute to Division 28 members. This provides me the opportunity of sharing my position with respect to APS membership, a position that I believe is consistent with that of most Division officers. I encourage Division 28 members who have an interest in the goals and activities of APS to join, as I have. APS has made remark- able progress since its inception, with over 7,000 members, a new Washington office, and a new journal soon to appear. On the other hand, I do not recommend that Psychophar- macology Division members give up their membership in APA and the Division. Among the benefits of continued association with APA are the excellent scientific programs at the annual convention, an opportunity to continue our success in the public policy area through effective represen- tation in Washington, a forum for behavioral science to impact on treatment and prevention in behavioral and substance abuse disorders, the collegial association with other scientists who remain in the Division, professional recognition through awards and promotion to Fellow s ~ a - tus, and the informative publications from both APA and the Division. I would also add that continued membership in APA will provide you the opportunity to shape the dircc-

tion of this large and important professional society repre- senting the interests of behavioral scientists. Each Division member needs to weigh the benefits, and increasing costs, of membership in APA and/or APS, and make his/her own decision.

ANIMAL WELFARE LEGISLATION

On Nov. 20, 1989, the Heflin bill ("Animal Research Facilities Protection Act of 1989") was passed by the Sen- ate. This legislation would make it a federal crime to break into any research facilities, steal laboratory animals, or destroy data or equipment. In order for this act to become law, a companion bill, Rep. Stenholm's HR 3270, must be passed by the House. In another development, Rep. Vin Weber (R-MN) is forming a group of members of Con- gress tentatively called the Animal Welfare Caucus, as a "common sense voice" in support of animal research. To urge your Representative to support the Stenholm bill or to participate in the Animal Welfare Caucus, write him/her at the U.S. House of Representatives, Washington DC 20515.

PSYCHOP COLOGY: COMING O w

Neil E. Gnmberg, Ph.D. Uniformed Services University of the Health Sciences

Walk with me through filthy rooms and hallways filled with the pungent odors of human urine and unwashed bodies. Look into eyes filled with apathy, despair, and sorrow in this depository of human misery. Be careful not to stumble on ghoulish living statues frozen with catatonia. Be on guard, because episodes of violence and aggression may explode around you without any warning at all. During the early 1950s, this was the state in the back wards of psychiatric hospitals where society's psychological lepers were incarcerated. This was reality before psychopharma- cology.

In the mid 1950s, chlorpromazine, reserpine, and the first wave of psychopharmacological therapeutic agents were introduced, and the early effects seemed miraculous. Because of these drugs, treatment and rehabilitation became possibilities, and the back wards were emptied. There was a new optimism regarding the prognosis of mentally ill patients, and as a result, there was a surge of funds to make living conditions humane and to do research to develop and improve psychopharmacological agents. The successful identification and development of these first drugs to treat mental illnesses are largely attributable to a particular basic scientific development of the time--namely,

the emphasis on measuring behavioral responses. This focus on outcomes, championed most notably by Joe Brady, was critical. The experimental analysis of behavior and the application of operant techniques to the study of potential drugs for treating mental illnesses were breakthroughs. By 1960, behavioral pharmacology was a meaningful discipline that offered unprecedented promise for the mentally ill.

In the 1960s behavioral pharmacology per se grew in influence and activity, and its value as a basic science with clinical significance became clear. But behavioral pharma- cology, with its exquisite controls and exact measures of behavioral determinants and responses, was soon to become only one aspect of the emerging psychopharmacol- ogy. The pharmaceutical industry, which had enjoyed remarkable success in the 1950s against infectious diseases, turned its attention to a search for pharmacological agents to treat cancers and mental illnesses. These scientific and financial interests quickened the pace of research and helped to expand the perspectives of investigations. Most importantly, psychopharmacology began to seriously con- sider relevant biochemical processes, such as the role of catecholamines and indoleamines, to develop new medica- tions, and to better understand the basic mechanisms underlying mental disorders. As a result of these develop- ments, psychopharmacology now included behavioral and biochemical assessments relevant to drugs to treat classic mental illnesses. But there was soon to be a further broad- ening of this young discipline in response to dramatic changes in American culture.

The use of psychopharmacological agents is, of course, not restricted to psychiatric wards. Mind-altering M s , including alcohol, opiates, amphetamines, and cocaine, have been widely used by the general public in this country for decades. But the recreational use of these drugs came to play a major role in cultural and political movements in the late 1960s. Marijuana and LSD became symbols of hippiedom, rock music, and the anti-Vietnam War move- ment. Yet, voluntary self-administration of these drugs by people without mental illnesses was not understood. What did these drugs do? Did they cause violence, criminal behavior, rebelliousness? Did they cause apathy, drain motivation, deteriorate cognitive abilities? Did they en- hance creativity? Why did people use them? And why was it so difficult to give them up? What caused dependence on these drugs? What caused drug withdrawal phenomena? These questions and the widespread use of mind-altering drugs forced psychopharmacology to broaden its scope. By 1970, drugs of addiction and all sorts of drugs that were self-administered by normal people had to be included in the work of psychopharmacologists.

In the 1970s biochemical psychopharmacology and

neuropsychopharmacology took off. Research attention to opiates and the discovery of the various endogenous opioids revealed possible explanations for drug dependence while furthering basic science as well. The identification of opioid receptors and the fact that there were multiple types of these receptors sparked theoretical as well as empirical advances in the study of many drugs. How receptor bind- ing could be changed by pharmacological antagonists, agonists, and even behavioral history became active areas of investigation. Psychopharmacology now was relevant to society at large and was revealing facts about brain func- tioning and how brain and behavior interrelated.

As someone trained in psychology and pharmacology in the 1970s, I felt fortunate to be able to incorporate what seemed then to be an enormous breadth of behavioral and biological approaches. I was especially enthusiastic about developments in psychopharmacology that could be used to study mechanisms of addiction and how these processes might relate on neurochemical and psychological levels to basic appetitive behaviors. I was thrilled by the challenge of trying to master multiple, interrelated disciplines, but I never imagined the scope of that goal that was soon to be revealed by scientific developments in the 1980s. I also did not fully appreciate at the time the paramount importance of the problem-driven style of research that I was learning in Stan Schachter's laboratory.

Recent advances in the neurosciences and molecular biology have provided us with an additional source of tools that were science fiction just 10 years ago. What we now know about receptor function, neuromodulation, and gene expression are worlds of new information. The techniques available to us to pursue psychopharmacology are now staggering. But there are dangers: specific techniques can become seductive, and methodological overspecialization can become an intellectual straight-jacket. To avoid these traps, we must follow the leads of Brady, Skinner, and Schachter. These scientists certainly have had their differ- ences. But they similarly focused on problem-driven and hypothesis-driven research along programmatic lines. It is the integration of theories and techniques into problem- focused approaches that will take us forward. We certainly must study the human condition on multiple levels, includ- ing: societal and cultural, group dynamics, individual condi- tioned and unconditioned behaviors, individual cognitions, physiological mechanisms, biochemical mechanisms, cen- tral versus peripheral nervous system involvement, and molecular mechanisms. But we must be sure to maintain and improve dialogues across these levels to insure that the right questions are being addressed in the laboratory and in the clinic. It is in this way that we will answer questions and will appropriately apply techniques rather than letting the techniques control the work.

Psychopharmacology has come of age; the back wards are gone. It is not only behavioral pharmacology, neuro- psychopharmacology, biochemical pharmacology, the study of conditioned behavior, the study of unconditioned behav- ior, work in vitro, work in vivo, or work in the clinic. It is all of these subdisciplines and approaches. It must also include cognitive neurosciences, computer modeling, and other developing areas. As long as the maturing of psycho- pharmacology includes the wisdom of thoughtful integra- tions and investigations, then before this century is over, psychopharmacology will have left a mark of such magni- tude that the human condition will unquestionably be im- proved.

ANNOUNCEMENT

The Third International Meeting of the European Behavioral Pharmacology Society will be held in Noordwij- kerhout, The Netherlands from June 27 to July 1, 1990. Deadline for submission of abstracts is February 15, 1990. Address requests for information to Dr. M.R. Kruk, Sylvius Laboratory, P.O. Box 9503, 23090 RA Leiden, The Nelher- lands.

OPEN POSITIONS

Fellowship in Substance Abuse Clinical Research. Applications are

being sought for a two-year program at Yale University with inpatient

and outpatient placements. Contact Thomas Kosten, M.D., 27 Sylvan

Ave., New Haven, CT 06519; (203) 785-0705.

Behavioral Medicine Postdoctoral Research Fellowship. The

University of Pittsburgh has fellowships currently available. Majority of

training is in the laboratory with training faculty and includes opportuni-

ties in Human Behavioral Pharmacology of Nicotine. Program also

includes didactic training in physiology/psycl~opl~ysiology, cardiovascular

pathophysiology, principles of behavior, and research methods/statistics.

Fellowships are for 1-3 years; stipends at current NIH levels of support.

Must be a U.S. citizen o r non-citizen national in accordance with NII-I

regulations for a NRSA fellowship award. Contact Karen Matthews,

Ph.D., Department of Psychiatry, University of Pittsburgh, 3811 0'IIara

Street, Pittsburgh, PA 15213, or call (412) 624-2041. EEOC/MF.

Postdoctoral Fellowship: A postdoctoral position is available for a

CNS pharmacologist/physiologist with interest in dopamine-related

research. Some experience with operant behavioral techniques and/or

measurement of cardiovascular function is desirable. The successful

applicant will be involved in ongoing behavioral projects and encouraged

to become an active member of a multi-disciplinary program to deter-

mine behavioral, neurochemical, and physiological effects of dopaminer-

gic drugs. Available immediately. Send CV and names of 3 references to

Jack Bergman, Div. of Behavioral Biology, Harvard Medical School/New

England Regional Primate Research Center, 1 Pine Hill Dr., Southbor-

ough, MA 01772. Harvard Medical School is an Equal Opportunity

Employer and specifically encourages applications from women and

minorities.

Postdoctoral Research Fellowship: The Behavioral Medicine

Laboratory of the Univ. of Michigan Dept. of Psychiatry announces the

availability of a 1-2 year postdoctoral research fellowship (starting 9/90)

in Human Psychopharmacology and Substance Abuse, with a particular

focus on nicotine. Trainee will collaborate on laboratory-based projects

examining smoking and other behaviors across the menstrual cycle,

predictors of ability to abstain from smoking, and/or studies using

pharmacological probes. Persons with Ph.D. (in hand or expected short-

ly) in experimental psychology, pharmacology, or other relevant disci-

plines are invited to apply. Send letter of interest, CV, and 3 letters of

recommendation to: Cynthia S. Pomerleau, Ph.D., Behavioral Medicine

Program, Univ. of Michigan Dept. of Psychiatry, Riverview Bldg., 900

Wall St., Ann Arbor, MI 48105; (313) 764-7152. The Univ. of Michigan is

an Equal Opportunity/Affirmative Action Employer.

Postdoctoral Position: The Smoking Research Group at the Univ.

of Pittsburgh has a position for a postdoctoral fellow. Includes responsi-

bility as director of a NIDA-funded research project on tobacco smoking,

nicotine dependence, and relapse. Also includes opportunities for partic-

ipation in scientific publications, participation in an interdisciplinary

behavioral medicine seminar, and development of candidate's own re-

search interests. A non-tenure-stream faculty appointment may be

extended to qualified candidates. Position begins Summer/Fall, 1990. A

minimum commitment of 2 years is needed; a longer tenure can be

negotiated. Salary is competitive. Candidates should have completed (or

be close to completing) Ph.D. in psychology or another behavioral

science. Knowledge of one of the following areas is desirable: drug use/

dependency, cigarette smoking/nicotine addiction, and/or drug abuse

treatment/relapse. Competence with PC-compatible computers (DOS,

database management) is also important. Send CV and statement of

interests to: Saul Shiffman, Ph.D., Clinical Psychology Center, 604 Old

Engineering Hall, U of Pittsburgh, Pittsburgh, PA 15260; (412) 624-1601.

Public Policy Fellowship. SPSSI (APA Division 9) invites applica-

tions for a one year Public Policy Fellowship. The Fellow represents

SPSSI in relevant policy activities and works with APA's legislative staff.

Activities include preparing legislative briefing materials, policy research,

advocating legislation, and SPSSI/APA committee activities. Qualifica-

tions: applicants must have a psychology Psy.D. or Ph.D., be a current

APA member, and join SPSSI before the appointment date (June 1,

1990). Award: one year appointment beginning June 1,1990 or later.

Stipend of 25,000 plus favorable benefit package. Must reside in Wash-

ington, D.C. area during Fellowship. Application: submit in triplicate (1)

a detailed vita, (2) names and addresses of 3 references, (3) 300-600 word

biographical statement of experience and interest in policy activities, and

(4) 300-600 word testimony on a social issue to a legislative body using

social science data or theory. Send materials, postmarked by March 1,

1990 to: Ms. Lynda J. Fuerstnau, Administrative Officer, SPSSI Central

Office, P.O. Box 1248, Ann Arbor, MI 48106-1248.

APPRECIATION FOR CORPORATE SPONSORSHIP OF DIVISION 28

Jack Henninefield Treasurer, Division 28

The Psychopharmacology Division of the American Psychological Association would like to express its great appreciation to the many corporate sponsors that help to fund our scientific and academic activities. This support has helped the Psychopharmacology Division to facilitate research and effectively disseminate information. Specific activities that are supported by this funding include the following: to organize interesting and effective programs on drugs and behavior at the Annual Convention of the APA, to invite outstanding leaders in the field both from industry and academia to address those attending the convention, to publish and distribute the quarterly Psycho- pharmacology Newsletter to our 1,200 members, Fellows, Corporate Affiliates, and officers in the 90,000 member American Psychological Association, to influence national policy on the usefulness of animal testing in the evaluation of the activity of drugs and compounds, to promote the already close interdependence between academic and industrial psychopharmacology, and to support, in general, those programs and activities both within and outside the American Psychological Association that relate to the growth and productivity of psychopharmacology.

Corporate sponsors during 1989 have included:

E.I. DuPont de Nemours & Company Hoechst-Roussell Pharmaceuticals Inc. Laderle Laboratories, Division of American Cyana-

mide Company Merrell Dow Pharmaceuticals Inc. Sohering Corporation G.D. Searle and Company Lakeside Pharmaceuticals Burroughs Wellcome Company Bristol-Meyers Company Reckitt & Colman Wyeth-Ayerst Research

CALL FOR FELLOW NOMINATIONS

The Executive Committee of Division 28 seeks nomi- nees for Fellow status in the Division. Any members who have made outstanding contributions to psychopharmacol- ogy are eligible for nomination. If you would like to be considered for fellow status, or if you know of any individu- als who you believe are appropriate for this APA honor, please send a copy of the C.V. to the Division 28 Member-

ship Chair, Stephen C. Fowler, Ph.D. (address listed on page 7).

CONVENTION '90

Warren Bickel, Ph.D. Program Chair, Division 28

The APA program in Boston is shaping up to be a very strong program for psychopharmacology. Already confirmed are invited addresses by Dr. Mendelson and Dr. Spealman, who will be discussing their latest research find- ings associated with drug dependence. There will also be Division 28's Presidential Symposium on the development of pharmacotherapies. Submissions are still being com- piled as of this writing; however, symposia will include:

AIDS Prevention Policy for IV Drug Abusers (W. Bailey, APA, Chair) Behavioral Modification of Drug Effects (C. Schindler, NIDA ARC, Chair) Drug Effects on Social Behavior (T. Kelly, Johns Hopkins University, Chair) Educational Requirements for Prescription Privi- leges (M. Kilbey, Wayne State University, Chair) Human Drug Discrimination (A. Olliveto, Univer- sity of Vermont, Chair) Self-Quitting and Smoking Cessation (J. Hughes, University of Vermont, Chair) Smoking Cessation and Weight Gain (S. Leischow, Palo Alto Center, Chair) Substance Abuse and the Media (J. Sorenson, UNCF, Chair)

Additionally, there will be several excellent New Fellow Addresses, presentations, and posters.

NAMES AND ADDRESSES:

Robert L. Balster, Ph.D. Dept. of Pharmacology Medical College of Virginia Box 613 Richmond, VA 23298 (804) 786-8402

Herbert Barry, Ph.D. Department of Pharmacology University of Pittsburgh 1110 Salk Hall Pittsburgh, PA 15261

. (412) 648-8563

Although the Science Weekend themes (Emotions, Individual Differences, and Decision Making) are not altogether conducive to psychopharmacology, our division will be participating via a symposium on the behavioral economics of drug self-administration. Collectively, this should be an excellent program for Division 28 members. A complete listing of the program will be printed in the summer issue of this newsletter.

An informal paper session will be held in the Division 28 Hospitality Suite. If you wish to participate, please contact Warren K. Bickel, Department of Psychiatry, University of Vermont, 1 South Prospect St., Burlington, VT 05401.

Advance registration and requests for convention housing must be submitted by June 26; forms will be in- cluded in the March issue of the American Psychologist. Persons with disabilities are urged to include a note specify- ing services needed; APA will provide a van with a lift for persons in wheelchairs, interpreters for hearing-impaired persons, and escorts/readers for persons with visual im- pairments.

UPDATE ON NEWSLETTER AFFILIATES

At its August 1989 meeting, the Division 28 Executive Committee established, on a trial basis, a new category of the Division entitled "Newsletter Affiliate." Newsletter Affiliates may receive this newsletter free of charge; membership in APA is not required. Any individual inter- ested in psychopharmacology may become a Newsletter Affiliate by sending name, affiliation, and mailing address to the Division 28 Membership Chair, Stephen C. Fowler, Ph.D. (address on page 7). As of December, 1989, sixteen individuals have taken advantage of this offer.

OFFICERS AND COMMITTEE CHAIRS

Warren K. Bickel, Ph.D. Dept. of Psychiatry, University of Vermont 1 S. Prospect Street Burlington, VT 05405 (802) 656-7889

Larry D. Byrd, Ph.D. Yerkes Regional Primate Research Center Emory University Atlanta, GA 30322 (404) 727-7730

Linda A. Dykstra, Ph.D. Department of Psychology University of North Carolina Chapel Hill, NC 27514 (919) 962-6595

Hugh L. Evans, Ph.D. Institute of Environmental Medicine 550 First Avenue New York, NY 10016 (914) 351-4249 or (212) 340-7300

Steven C. Fowler, Ph.D. Dept. of Psychology, University of Mississippi University, Mississippi 38677 (601) 232-7383

John G. Grabowski, Ph.D. Department of Psychiatry and Behavioral Science University of Texas Health Science Center 1300 Moursund, Room 341 Houston, TX 77030 (713) 792-7925

Sharon M. Hall, Ph.D. CSBS Health Psychology, Room 204 University of California, San Francisco Box 8044 San Francisco, CA 94143 (415) 476-7574 or 681-8080 (ext. 574)

Jack E. Henningfield, Ph.D. NIDA Addiction Research Center P.O. Box 5180 Baltimore, MD 21224 (301) 550-1494

Stephen T. Higgins, Ph.D. Department of Psychiatry University of Vermont 1 S. Prospect Street Burlington, W 05405 (802) 656-7884

Chris Ellyn Johanson, Ph.D. Uniformed Services University of the

Health Sciences 430 Jones Bridge Road Bethesda, MD 20814 (202) 295-0972

Marlyne M. Kilbey, Ph.D. Department of Psychology Wayne State University 71 W. Warren Detroit, MI 48207 (313) 577-2802

Klaus A. Miczek, PH.D. Department of Psychology Tufts University Medford, MA 02155 (617) 381-3414

Donald A. Overton, Ph.D. Departments of Psychology and Psychiatry Weiss Hall, Temple University 13th & Columbia Ave. Philadelphia, PA 19122 (215) 787-1534

Cynthia S. Pomerleau, Ph.D. Department of Psychiatry/Behavioral Medicine The University of Michigan 900 Wall Street Ann Arbor, MI 48105-0722 (313) 764-7152

Barbara L. Slifer, Ph.D. Department of Psychology University of New Orleans/Lakefront New Orleans, LA 70148 (504) 286-6771

Robert L. Sprague, Ph.D. Institute for Child Behavior & Development University of Illinois 51 Gerty Drive Champaign, IL 61820 (217) 333-4123

Ronald W. Wood, Ph.D. Institute of Environmental Medicine New York University 550 First Avenue New York, NY 10016 (914) 351-4249

Alice M. Young, Ph.D. Wayne State University Department of Psychology 71 West Warren Avenue Detroit, MI 48202 (313) 577-3290-

DIVISION 28 OFFICERS DIVISION 28 OFFICERS (cont.)

Elected:

President

President-Elect

Past-President

Council Representative

Members-at-large

Appointed:

Treasurer

Secretary

Program Chair, 1990

Past-Program Chair

Incoming Program Chair

Newsletter Editor

Membership Chair

CPDD Liaison

Public Information

ASPET Liaison Officers

APA Public Affairs Liaison

APS Liaison

Committee on Nominations

Robert L. Balster

Klaus Miczek

Linda Dykstra

John G. Grabowski

Sharon M. Hall

Alice M. Young

Robert Sprague

Jack E. Henningfield

Stephen T. Higgins

Warren K. Bickel

Barbara L. Slifer

David Penetar

Cynthia S. Pomerleau

Stephen C. Fowler

Robert L. Balster

John G. Grabowski

Alice M. Young

Chris Johanson

Donald Overton

Larry D. Byrd

Term on

Council

NTTSC Ronald W. Wood 8189-8/91

Committee on Animal Research Hugh L. Evans 8/89-8191

Committee on Prescript. Priv. Marlyne Kilbey 8/89-8191

Centennial Officer Herbert Barry 8\89-8191

SUBMISSION OF COPY FOR THE NEWSLETTER

Readers are invited to submit articles and information of general interest

to Division 28 members. Copy may be submitted typed double-spaced

on standard bond paper or word-processed on IBM-compatible equip-

ment; be sure to include hard copy in case the diskette is damaged in the

mail. Submit materials to:

Cynthia S. Pomerleau, Ph.D.

Behavioral Medicine Program

University of Michigan Department of Psychiatry

Riverview Building, 900 Wall Street

Ann Arbor, MI 48105-0722

(313) 764-7152

The Newsletter is published on a quarterly basis and will appear 4-6 weeks

after each deadline. Deadlines for submission of materials are:

Fall issue: September 15 Spring Issue: March 15

Winter issue: December 15 Summer Issue: June 15

Cynthia S . Pomerleau, Ph.D. Editor, Division 28 Newsletter Behavioral Medicine Program University of Michigan Department of Psychiatry Riverview Building, 900 Wall Street Ann Arbor, MI 48105